FDA Approves Avastin for Platinum-Sensitive Recurrent Ovarian Cancer

(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone.

The approval is based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive, recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone.

Previously, Avastin was approved in the United States for the treatment of women with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.

Read more at OncLive.

Posted on in Research